These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 9784093)

  • 1. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.
    Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Schafer PH; Siekierka JJ
    J Med Chem; 1998 Oct; 41(22):4196-8. PubMed ID: 9784093
    [No Abstract]   [Full Text] [Related]  

  • 2. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
    Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
    J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
    Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes.
    Schafer PH; Wang L; Wadsworth SA; Davis JE; Siekierka JJ
    J Immunol; 1999 Jan; 162(2):659-68. PubMed ID: 9916683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
    Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
    Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR
    J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
    Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
    J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells.
    Feoktistov I; Goldstein AE; Biaggioni I
    Mol Pharmacol; 1999 Apr; 55(4):726-34. PubMed ID: 10101031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrroles and other heterocycles as inhibitors of p38 kinase.
    de Laszlo SE; Visco D; Agarwal L; Chang L; Chin J; Croft G; Forsyth A; Fletcher D; Frantz B; Hacker C; Hanlon W; Harper C; Kostura M; Li B; Luell S; MacCoss M; Mantlo N; O'Neill EA; Orevillo C; Pang M; Parsons J; Rolando A; Sahly Y; Sidler K; O'Keefe SJ
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2689-94. PubMed ID: 9873604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
    Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
    J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of lipopolysaccharide-induced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor.
    Kobayashi H; Yoshida R; Kanada Y; Fukuda Y; Yagyu T; Inagaki K; Kondo T; Kurita N; Suzuki M; Kanayama N; Terao T
    J Periodontal Res; 2005 Dec; 40(6):461-8. PubMed ID: 16302924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.
    Mbalaviele G; Sommers CD; Bonar SL; Mathialagan S; Schindler JF; Guzova JA; Shaffer AF; Melton MA; Christine LJ; Tripp CS; Chiang PC; Thompson DC; Hu Y; Kishore N
    J Pharmacol Exp Ther; 2009 Apr; 329(1):14-25. PubMed ID: 19168710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
    Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
    J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
    Badger AM; Bradbeer JN; Votta B; Lee JC; Adams JL; Griswold DE
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1453-61. PubMed ID: 8968371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent, orally absorbed glucagon receptor antagonists.
    de Laszlo SE; Hacker C; Li B; Kim D; MacCoss M; Mantlo N; Pivnichny JV; Colwell L; Koch GE; Cascieri MA; Hagmann WK
    Bioorg Med Chem Lett; 1999 Mar; 9(5):641-6. PubMed ID: 10201821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
    Liu C; Lin J; Wrobleski ST; Lin S; Hynes J; Wu H; Dyckman AJ; Li T; Wityak J; Gillooly KM; Pitt S; Shen DR; Zhang RF; McIntyre KW; Salter-Cid L; Shuster DJ; Zhang H; Marathe PH; Doweyko AM; Sack JS; Kiefer SE; Kish KF; Newitt JA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    J Med Chem; 2010 Sep; 53(18):6629-39. PubMed ID: 20804198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.